Health Trials

Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent

4

Review clinical trials related to Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

HEM-iSMART E: Capivasertib + Venetoclax + Dexamethasone in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol E is a phase I/II trial evaluating the safety and efficacy of capivasertib + venetocolax in combination with dexamethasone in children and AYA with R/R ped ALL/LBL whose tumor present with alterations of the PAM pathway, or lacking any mutations.

Participants needed: 42
Trial details
Phase: Phase 1, Phase 2Age: 2-21Biological sex: AllType: InterventionalSponsor: Princess Maxima Center for Pediatric OncologyUpdated: Sep 16, 2025
Eligibility criteria

Children ≥ 2 years and ≤ 18 years of age at the time of first diagnosis and less... [+11]

Pregnancy or positive pregnancy test (urine or serum) in females of childbearing... [+23]

Read more
Status: Recruiting

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol B is a phase I/II trial evaluating the safety and efficacy of dasatinib + venetocolax in combination with dexamethasone + Cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the MAPK/SRC pathway.

Participants needed: 26
Trial details
Phase: Phase 1, Phase 2Age: 1-21Biological sex: AllType: InterventionalSponsor: Princess Maxima Center for Pediatric OncologyUpdated: Sep 16, 2025Locations: 33
Eligibility criteria

Children between 1 year (≥ 12 months) and 18 years of age at the time of first d... [+10]

Pregnancy or positive pregnancy test (urine or serum) in females of childbearing... [+23]

Read more
Status: Recruiting

HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol C is a phase I/II trial evaluating the safety and efficacy of ruxolitinib and venetoclax in combination with dexamethasone, cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the IL7R/JAK-STAT pathway.

Participants needed: 26
Trial details
Phase: Phase 1, Phase 2Age: 1-21Biological sex: AllType: InterventionalSponsor: Princess Maxima Center for Pediatric OncologyUpdated: Sep 16, 2025Locations: 33
Eligibility criteria

Children between 1 year (≥ 12 months) and 18 years of age at the time of first d... [+9]

Pregnancy or positive pregnancy test (urine or serum) in females of childbearing... [+26]

Read more
Status: Recruiting

HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

HEM-iSMART is a master protocol which investigates multiple investigational medicinal products in children, adolescents and young adults (AYA) with relapsed/refractory (R/R) ALL and LBL. Sub-protocol D is a phase I/II trial evaluating the safety and efficacy of trametinib in combination with dexamethasone, cyclophosphamide and cytarabine in children and AYA with R/R ped ALL/LBL whose tumor present with alterations in the RAS-RAF-MAPK pathway.

Participants needed: 26
Trial details
Phase: Phase 1, Phase 2Age: 1-21Biological sex: AllType: InterventionalSponsor: Princess Maxima Center for Pediatric OncologyUpdated: Sep 16, 2025Locations: 36
Eligibility criteria

Children between 1 year (≥ 12 months) and 18 years of age at the time of first d... [+10]

Pregnancy or positive pregnancy test (urine or serum) in females of childbearing... [+19]

Read more